On January 7, 2026, Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced promising interim results from an ongoing Phase 1 clinical trial of MRT-8102, a novel NEK7-directed molecular glue degrader (MGD). The data indicates a significant reduction in high-sensitivity C-reactive protein (hsCRP) levels among subjects at elevated cardiovascular disease (CVD) risk, suggesting a potential breakthrough in the treatment of inflammatory conditions associated with the NLRP3 inflammasome.

2. Key Findings from the Interim Data

The interim analysis highlights a remarkable 85% decrease in median hsCRP levels after just four weeks of treatment with MRT-8102. Notably, 94% of subjects achieved hsCRP levels below the 2 mg/L threshold, which is critical for cardiovascular risk assessment. The baseline median hsCRP level among participants was recorded at 6.3 mg/L, notably higher than levels seen in traditional clinical benchmarks.

Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics, expressed enthusiasm about the findings, stating, “These remarkable interim data... demonstrate for the first time that treatment with an oral molecular glue degrader of NEK7 led to levels of CRP reduction comparable to those previously reported with biologic therapies.” This positions MRT-8102 as a potential best-in-class therapeutic option targeting the NLRP3/IL-1/IL-6 inflammatory pathway.

Study Design and Cohort Details

The Phase 1 study includes randomized, double-blind, placebo-controlled cohorts focused on both single ascending dose (SAD) and multiple ascending dose (MAD) administrations. The SAD cohorts comprised 48 subjects, while the MAD cohorts included 40 subjects. In Part 3, which specifically targets individuals with increased CVD risk, 24 subjects have completed the four-week dosing regimen.

Efficacy and Safety Profile

The data revealed substantial and consistent degradation of NEK7 across all dosing levels, ranging from 5 to 400 mg daily. Corresponding reductions in inflammatory markers IL-1β and IL-6 were also observed, with IL-6 levels dropping by a median of 55% and the safety profile remaining favorable. Adverse events reported were mild to moderate and self-resolving, with no evidence of increased infection risk linked to MRT-8102.

3. Next Steps and Future Studies

Filip Janku, M.D., Ph.D., Chief Medical Officer, announced the expansion of the proof-of-concept GFORCE-1 study, aimed at accelerating the upcoming Phase 2 (GFORCE-2) study in patients with atherosclerotic cardiovascular disease (ASCVD). Results from the GFORCE-1 study are anticipated in the second half of 2026. Additionally, Monte Rosa is exploring further Phase 2 studies in conditions such as metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis.

Upcoming Milestones

Monte Rosa has outlined several corporate milestones for 2026, focusing on both immunology and oncology programs. Key initiatives include:

Data release from the GFORCE-1 study in H2 2026.

Initiation of the GFORCE-2 study of MRT-8102 in ASCVD.

Collaboration with Novartis for multiple Phase 2 studies of VAV1-directed MGD MRT-6160.

Submission of IND applications for various new drug candidates.

4. Investor Engagement

Monte Rosa Therapeutics will host a conference call and webcast presentation at 8:00 a.m. ET on January 7, 2026, to discuss these interim results and future plans.

5. Conclusion

The interim data for MRT-8102 presents a compelling case for the drug's potential to revolutionize treatment for cardiovascular and inflammatory diseases. As Monte Rosa Therapeutics advances its clinical trials, the biopharmaceutical industry will be keenly observing its progress, with hopes of a transformative impact on patient care in chronic inflammatory conditions.

Original press release